PT  - JOURNAL ARTICLE
AU  - Wong, Irene O. L.
AU  - Wong, Cherry
AU  - Mak, Nelly
AU  - Dai, Alan
AU  - Xiao, Jingyi
AU  - Wu, Peng
AU  - Ni, Michael Y.
AU  - Liao, Qiuyan
AU  - Cowling, Benjamin J.
TI  - Assessment of the impact of the Vaccine Pass Policy on COVID-19 vaccine hesitancy and uptake among Chinese adults in Hong Kong
AID  - 10.1101/2023.12.03.23299354
DP  - 2023 Jan 01
TA  - medRxiv
PG  - 2023.12.03.23299354
4099  - http://medrxiv.org/content/early/2023/12/04/2023.12.03.23299354.short
4100  - http://medrxiv.org/content/early/2023/12/04/2023.12.03.23299354.full
AB  - Background Recognising the importance of attaining high vaccine coverage to mitigate the COVID-19 impact, a Vaccine Pass scheme was implemented during and after the first large Omicron wave in Hong Kong in early 2022 requiring three doses by June 2022. We evaluated the impact of the Vaccine Pass policy on vaccine uptake in adults.Methods We analyzed patterns in vaccine uptake and hesitancy using local data from the population vaccine registry and 32 cross-sectional surveys conducted from October 2021 to December 2022. We examined the association of Vaccine Pass phases with vaccine uptake, taking into account covariables including self-risk perception, perceived self-efficacy in preventing COVID-19 and trust in government in pandemic control as well as physical distancing measures and demographics.Findings The uptake of primary series and third doses was significantly associated with stages of Vaccine Pass implementation, and other statistically significant drivers included age group, chronic condition, higher perceived personal susceptibility to COVID-19, higher trust in government, and higher educational attainment. Older adults (≥65y) were less likely to be vaccinated against COVID-19, compared to adults aged 18-44 years.Interpretation Vaccine uptake in older adults was observed to have increased by a greater extent after the policy announcement and implementation, which occurred during and after a large Omicron wave with high mortality in older ages in early 2022. Since the policy withdrawal the uptake of further booster doses has been very low in all ages. Improving voluntary booster uptake in older adults should be prioritized.Funding Health and Medical Research Fund, Hong Kong.Competing Interest StatementB. J. C. consults for AstraZeneca, Fosun Pharma, GlaxoSmithKline, Haleon, Moderna, Novavax, Pfizer, Roche, and Sanofi Pasteur, and has received research funding from Fosun Pharma. All other authors report no potential conflicts.Funding StatementWe received funding from the Health Bureau, The Government of the Hong Kong Special Administrative Region (Ref. No.: COVID19F04; COVID19F11), and by the Theme-Based Research Scheme T11-705/21-N of the Research Grants Council of the Hong Kong Special Administrative Region, China. B. J. C. is supported by a RGC Senior Research Fellow Scheme grant (HKU SRFS2021-7S03) from the Research Grants Council of the Hong Kong Special Administrative Region, China.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Our study protocol was approved by the Institutional Research Board of the University of Hong Kong (ref: US 20-095).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesData will be made publicly available after publication of peer-reviewed article